• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Azurity Pharmaceuticals Absorbs Slayback Pharma


Company expects to yield a significant number of new medicine launches from the acquisition.

Business Handshake Agreement Partnership Deal Team Concept. Image Credit: Adobe Stock Images/Rawpixel.com

Image Credit: Adobe Stock Images/Rawpixel.com

Azurity Pharmaceuticals, Inc. broke the news that it has officially acquired Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making it a wholly owned subsidiary. According to Azurity, the acquisition is expected to realize its purpose of serving overlooked patients, hoping to yield a significant number of new medicine launches over the coming years.

"I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients," said Richard Blackburn, CEO, Azurity. "The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs."

Reference: Azurity Pharmaceuticals Acquires Slayback Pharma. PR Newswire. September 27, 2023. Accessed September 27, 2023. https://www.prnewswire.com/news-releases/azurity-pharmaceuticals-acquires-slayback-pharma-301940279.html

Related Videos
Related Content